FLASCO

Corporate Members

Diamond Elite

Diamond

Platinum

Gold

Latest News

Florida Cancer Specialists partners with Cedar to improve the patient financial experience

Personalized billing and payment platform will enable an improved financial experience for oncology patients across the growing FCS community-based provider network Fort Myers, Fla., February 10, 2020 — Florida Cancer Specialists & Research Institute (FCS) and Cedar, a patient engagement and payment technology platform, today announced that they are partnering to modernize the on-line payment experience...

taiho oncology

Taiho Oncology Announcement

On behalf of Taiho Oncology, Inc., we are pleased to inform you that a corporate press release, “Astex Pharmaceuticals announces U.S. Food and Drug Administration (FDA) acceptance for review of an NDA for the combination oral hypomethylating agent cedazuridine and decitabine (ASTX727 or oral C-DEC), for the treatment of MDS and CMML” has been issued...

2020 Patient Assistance & Reimbursement Guide

ACCC Patient Assistance and Reimbursement

IMPROVED FUNCTIONALITY & NAVIGATION!  To Download your copy visit the ACCC site Today! Hot links on the “Table of Contents” allow you to go straight to the drug manufacturer’s patient assistance and reimbursement page OR click on a specific drug and go right to that drug’s patient assistance and reimbursement program. Plus, a “Table of...

FDA grants approval for TAZVERIK

Epizyme announces that U.S. Food and Drug Administration (FDA) has granted accelerated approval of TAZVERIK (tazemetostat) for the treatment of adults and pediatric patients age 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for resection, based on overall response rate and duration of response in a Phase 2 clinical trial.  You...

FDA approves Keytruda for treatment of patients with BCG

Merck is pleased to announce that KEYTRUDA® (pembrolizumab) has been approved by the FDA for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. PD-L1 diagnostic testing is not...

Who’s Online

There are no users currently online